The Latest Breaking News from TransMedics Group

TransMedics Group saw an improvement in its IBD SmartSelect Composite Rating Friday, from 94 to 97.

A Relative Strength Rating upgrade for TransMedics Group shows improving technical performance.

Morning Markets The S&P 500 Index ( $SPX ) ( SPY ) is up +0.28%, the Dow Jones Industrials Index ( $DOWI ) ( DIA ) up +0.21%, and the Nasdaq 100 Index ( $IUXX ) ( QQQ ) is up +0.77%. Stocks this morning are higher. This is despite...

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.16%, and Dec Nasdaq 100 E-Mini futures (NQZ2 3) are up +0.04%. Stock index futures this morning are mixed after comments Monday night from Minneapolis Fed President Kashkari dampened hopes that the Fed was done raising interest rates. Also,...

Gainers

Upgrades

TransMedics Group (NASDAQ:TMDX) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings TransMedics Group reported in-line EPS of $-0.38 versus an estimate of $-0.38.

TransMedics Group (NASDAQ:TMDX) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that TransMedics Group will report an earnings per share (EPS) of $-0.38.

TransMedics Group, Inc. (NASDAQ: TMDX) received premarket approval (PMA) from U.S. Food and Drug Administration (FDA) for its OCS™ Heart System in favour of use with organs from donors after circulatory death (DCD).